Company / Operating Cash Flow
Travere Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$37.8M
FY2025
5-year range
-$280.0M / $37.8M
FY2021-FY2025
Trend
+115.9%
vs FY2024
Sector context
#68 of 216
Health Care
What the data says
At $38M, Travere Therapeutics, Inc.'s operating cash flow ranks #68 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$280M in FY2023 to $38M in FY2025.
Based on SEC 10-K filings.
$38M in FY2025.
Improved from -$280M to $38M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#68 of 216 in Health CareTop 31% of 216This company $37.8M Sector average $658.7M
▼
-94.3% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 115.9% year-over-year.
- Ranks #68 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $37.8M | +115.9% |
| FY2024 | -$237.5M | +15.2% |
| FY2023 | -$280.0M | -50.3% |
| FY2022 | -$186.3M | -220.0% |
| FY2021 | -$58.2M | -133.2% |
| FY2020 | -$25.0M | -437.1% |
| FY2019 | $7.4M | +315.1% |
| FY2018 | -$3.4M | -147.7% |
| FY2017 | -$1.4M | +97.0% |
| FY2016 | -$45.9M | -3200.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026